Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014–2020

P Bach, M Bawa, C Grant, MJ Milloy… - International Journal of …, 2022 - Elsevier
Abstract Background Buprenorphine-naloxone (BUP-NX) is a first-line treatment for opioid
use disorder and has a superior safety profile compared to other forms of opioid agonist …
被引用次数：3 相关文章
[HTML] nih.gov

[HTML][HTML] AVAILABILITY AND USE OF NON-PRESCRIBED BUPRENORPHINE-NALOXONE IN A CANADIAN SETTING, 2014–2020

P Bach, M Bawa, C Grant, MJ Milloy… - The International journal …, 2022 - ncbi.nlm.nih.gov
Background Buprenorphine-naloxone (BUP-NX) is a first-line treatment for opioid use
disorder and has a superior safety profile compared to other forms of opioid agonist therapy …

Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020

P Bach, M Bawa, C Grant… - … journal on drug …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Buprenorphine-naloxone (BUP-NX) is a first-line treatment for opioid use
disorder and has a superior safety profile compared to other forms of opioid agonist therapy …

Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.

P Bach, M Bawa, C Grant, MJ Milloy… - … International Journal on …, 2021 - europepmc.org
Background Buprenorphine-naloxone (BUP-NX) is a first-line treatment for opioid use
disorder and has a superior safety profile compared to other forms of opioid agonist therapy …